EUVIMEDEUVIMED entdecken
Open Access

Medicaid Expansion and Restriction Policies for Hepatitis C Treatment

Nathan W Furukawa, Susan Z Ingber, Hasan Symum, Karina K Rapposelli, Eyasu H Teshale, William W Thompson, Weiming Zhu, Henry W Roberts, Neil Gupta

JAMA Network Open · 2024

DOI: 10.1001/jamanetworkopen.2024.22406 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, 2024. Verfasst von Nathan W Furukawa und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Viral Hepatitis, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, G…. Hauptthemen laut MEDLINE: Medicaid, Antiviral Agents. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Hepatitis C can be cured with direct-acting antivirals (DAAs), but Medicaid programs have implemented fibrosis, sobriety, and prescriber restrictions to control costs. Although restrictions are easing, understanding their association with hepatitis C treatment rates is crucial to inform policies that increase access to lifesaving treatment.

Objective

To estimate the association of jurisdictional (50 states and Washington, DC) DAA restrictions and Medicaid expansion with the number of Medicaid recipients with filled prescriptions for DAAs. Design, Setting, and Participants This cross-sectional study used publicly available Medicaid documents and claims data from January 1, 2014, to December 31, 2021, to compare the number of unique Medicaid recipients treated with DAAs in each jurisdiction year with Medicaid expansion status and categories of fibrosis, sobriety, and prescriber restrictions. Medicaid recipients from all 50 states and Washington, DC, during the study period were included. Multilevel Poisson regression was used to estimate the association between Medicaid expansion and DAA restrictive policies on jurisdictional Medicaid DAA prescription fills. Data were analyzed initially from August 15 to November 15, 2023, and subsequently from April 15 to May 9, 2024. Exposures Jurisdictional Medicaid expansion status and fibrosis, sobriety, and prescriber DAA restrictions. Main Outcomes and Measures Number of people treated with DAAs per 100 000 Medicaid recipients per year.

Results

A total of 381 373 Medicaid recipients filled DAA prescriptions during the study period (57.3% aged 45-64 years; 58.7% men; 15.2% non-Hispanic Black and 52.2% non-Hispanic White). Medicaid nonexpansion jurisdictions had fewer filled DAA prescriptions per 100 000 Medicaid recipients per year than expansion jurisdictions (38.6 vs 86.6; adjusted relative risk [ARR], 0.56 [95% CI, 0.52-0.61]). Jurisdictions with F3 to F4 (34.0 per 100 000 Medicaid recipients per year; ARR, 0.39 [95% CI, 0.37-0.66]) or F1 to F2 fibrosis restrictions (61.9 per 100 000 Medicaid recipients per year; ARR, 0.62 [95% CI, 0.59-0.66]) had lower treatment rates than jurisdictions without fibrosis restrictions (94.8 per 100 000 Medicaid recipients per year). Compared with no sobriety restrictions (113.5 per 100 000 Medicaid recipients per year), 6 to 12 months of sobriety (38.3 per 100 000 Medicaid recipients per year; ARR, 0.65 [95% CI, 0.61-0.71]) and screening and counseling requirements (84.7 per 100 000 Medicaid recipients per year; ARR, 0.87 [95% CI, 0.83-0.92]) were associated with reduced treatment rates, while 1 to 5 months of sobriety was not statistically significantly different. Compared with no prescriber restrictions (97.8 per 100 000 Medicaid recipients per year), specialist consult restrictions was associated with increased treatment (66.2 per 100 000 Medicaid recipients per year; ARR, 1.05 [95% CI, 1.00-1.10]), while specialist required restrictions were not statistically significant. Conclusions and Relevance In this cross-sectional study, Medicaid nonexpansion status, fibrosis, and sobriety restrictions were associated with a reduction in the number of people with Medicaid who were treated for hepatitis C. Removing DAA restrictions might facilitate treatment of more people diagnosed with hepatitis C.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MedicaidAntiviral AgentsHumansUnited StatesCross-Sectional StudiesMaleFemaleMiddle AgedHepatitis CAdultHealth PolicyHealth Services Accessibility

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Division of Viral Hepatitis, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia.

Zitieren

APA

Furukawa, N. W., Ingber, S. Z., Symum, H., Rapposelli, K. K., Teshale, E. H., Thompson, W. W., Zhu, W., Roberts, H. W., & Gupta, N. (2024). Medicaid Expansion and Restriction Policies for Hepatitis C Treatment. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2024.22406

Vancouver

Furukawa NW, Ingber SZ, Symum H, Rapposelli KK, Teshale EH, Thompson WW, et al. Medicaid Expansion and Restriction Policies for Hepatitis C Treatment. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2024.22406

BibTeX
@article{Furukawa2024,
  author = {Furukawa, Nathan W and Ingber, Susan Z and Symum, Hasan and Rapposelli, Karina K and Teshale, Eyasu H and Thompson, William W and Zhu, Weiming and Roberts, Henry W and Gupta, Neil},
  title = {Medicaid Expansion and Restriction Policies for Hepatitis C Treatment},
  journal = {JAMA Network Open},
  year = {2024},
  doi = {10.1001/jamanetworkopen.2024.22406}
}
Kostenlos starten →